Analysts Set Edwards Lifesciences Corporation (NYSE:EW) PT at $100.27

Edwards Lifesciences Corporation (NYSE:EW) has received an average recommendation of “Moderate Buy” from the twenty-three analysts that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $100.2727.

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Evercore reissued an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th.

Insider Buying and Selling

In other news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,045 shares of company stock valued at $457,749 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $266,000. NewEdge Advisors LLC raised its holdings in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after buying an additional 2,665 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after buying an additional 58,988 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after buying an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

EW stock opened at $90.00 on Tuesday. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The company has a market cap of $51.82 billion, a P/E ratio of 51.72, a PEG ratio of 2.36 and a beta of 0.85. The firm has a 50-day moving average of $89.73 and a 200 day moving average of $85.49. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts forecast that Edwards Lifesciences will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.